

Table S1. Histomorphometric characteristics of the examined subgroups of patients with KOA prior to and 18 months after the injection.

	PRP subgroup		SVF subgroup		p (Mann-Whitney U-test)
	Prior to injection	18 months after injection	Prior to injection	18 months after injection	
BV. %					
Tibia	31.2 [21.3;35.7]	34.7 [28.2;37.1] <b>p=0.099<sup>1</sup></b>	28.1 [24.4;38.7]	46.9 [41;55] <b>p=0.001<sup>1*</sup></b>	p=0.595 <sup>2</sup> <b>p&lt;0.001<sup>3*</sup></b>
Femur	23.7 [20.3;29.6]	29.2 [22.2;31.7] p <sup>1</sup> =0.271	21.8 [17.7;29.4]	21.4 [19.2;25.4] p <sup>1</sup> =0.532	p=0.305 <sup>2</sup> <b>p=0.004<sup>3*</sup></b>
Cr.V. %					
Tibia	31.7 [26.6;38.2]	18.6 [15.6;23.9] <b>p&lt;0.001<sup>1*</sup></b>	30 [28.6;34.2]	11.3 [10.6;15.2] <b>p<sup>1</sup>&lt;0.001<sup>1*</sup></b>	p=0.389 <sup>2</sup> <b>p&lt;0.001<sup>3*</sup></b>
Femur	16.7 [14.4; 23.6]	39 [32.7;41.5] <b>p&lt;0.001<sup>1*</sup></b>	20.1 [15.7;28.7]	24.6 [23.3;25.6] p <sup>1</sup> =0.211	p=0.116 <sup>2</sup> <b>p&lt;0.001<sup>3*</sup></b>
Tr.V. %					
Tibia	62.2 [60.1;70.3]	79.9 [76.8;88.9] <b>p&lt;0.001<sup>1*</sup></b>	79.6 [68.2;84.8]	85.8 [83.1;86.3] <b>p=0.008<sup>1*</sup></b>	<b>p&lt;0.001<sup>2*</sup></b> p=0.148 <sup>3</sup>
Femur	78.6 [76.6;82.5]	79 [76.9;82.6] p <sup>1</sup> =0.865	70.4 [66.1;74.6]	86.6 [82.7;88.4] <b>p&lt;0.001<sup>1*</sup></b>	<b>p&lt;0.001<sup>2*</sup></b> <b>p&lt;0.001<sup>3*</sup></b>
Cr.Wi. mm					
Tibia	1.4 [1;1.6]	0.54 [0.52;0.59] <b>p&lt;0.001<sup>1*</sup></b>	0.47 [0.42;0.68]	1 [0.68;1.24] <b>p=0.001<sup>1*</sup></b>	<b>p&lt;0.001<sup>2*</sup></b> <b>p&lt;0.001<sup>3*</sup></b>
Femur	0.75 [0.54;0.84]	0.62 [0.51;0.74] p=0.244 <sup>1</sup>	0.46 [0.33;0.52]	0.74 [0.72;0.78] <b>p&lt;0.001<sup>1*</sup></b>	<b>p&lt;0.001<sup>2*</sup></b> <b>p=0.014<sup>3</sup></b>
Ch.Wi mm					
Tibia	0.4 [0.4;0.5]	1.06 [0.68;1.18] <b>p&lt;0.001<sup>1*</sup></b>	0.66 [0.52;0.83]	1.04 [0.94;1.22] <b>p&lt;0.001<sup>1*</sup></b>	<b>p&lt;0.001<sup>2*</sup></b> p=0.436 <sup>3</sup>
Femur	1.14 [0.95;1.64]	1.51 [1.31;1.92] <b>p=0.019<sup>1*</sup></b>	0.8 [0.61;0.86]	0.89 [0.83;0.93] <b>p=0.009<sup>1*</sup></b>	p=0.004 <sup>2*</sup> <b>p&lt;0.001<sup>3*</sup></b>
Tr.Th. µm					
Tibia	0.1 [0.07;0.14]	0.14 [0.13;0.17] <b>p=0.006<sup>1*</sup></b>	0.12 [0.1;0.15]	0.16 [0.14;0.26] <b>p=0.001<sup>1*</sup></b>	p=0.249 <sup>2</sup> <b>p=0.021<sup>3*</sup></b>
Femur	0.14 [0.11;0.16]	0.13 [0.13;0.14] p=0.293 <sup>1</sup>	0.12 [0.1;0.15]	0.16 [0.09;0.23] <b>p=0.051<sup>1*</sup></b>	p=0.161 <sup>2</sup> p=0.126 <sup>3</sup>

Tr.Sp. $\mu\text{m}$ Tibia	1.06 [0.98;1.2]	0.92 [0.72;1.07] <b>p=0.002<sup>1</sup>*</b>	1.01 [0.97;1.1]	0.76 [0.63;0.86] <b>p&lt;0.001<sup>1</sup>*</b>	p=0.217 <sup>2</sup> <b>p=0.009<sup>3</sup>*</b>
Femur	0.9 [0.8;1.02]	0.88 [0.72;0.97] p=0.177 <sup>1</sup>	0.88 [0.64;0.96]	0.77 [0.58;0.82] p=0.125 <sup>1</sup>	p=0.161 <sup>2</sup> <b>p=0.007<sup>3</sup>*</b>
Tr.N. n/mm <sup>3</sup> Tibia	0.65 [0.35;0.72]	1.14 [0.37;1.96] <b>p=0.009<sup>1</sup>*</b>	0.81 [0.55;0.97]	0.75 [0.66;0.81] p=0.532 <sup>1</sup>	<b>p=0.026<sup>2</sup>*</b> p=0.148 <sup>3</sup>
Femur	0.9 [0.83;1.19]	1.22 [1.04;1.29] <b>p=0.017<sup>1</sup>*</b>	1.06 [1.02;1.09]	1.54 [0.88;1.83] <b>p=0.008<sup>1</sup>*</b>	p=0.202 <sup>2</sup> <b>p=0.029<sup>3</sup>*</b>

Note: All statistically significant differences are indicated with an asterisk (\*)

<sup>1</sup> - Differences between values before and 18 months after the injection;

<sup>2</sup> - Differences between subgroups before injection

<sup>3</sup> - Differences between subgroups after the injection

BV, bone volume; Cr.V, subchondral bone volume; Tr.V, trabecular bone volume; Cr.Wi, subchondral plate height; Ch.Wi, articular cartilage thickness. Tr.Th, trabecular thickness; Tr.Sp, intertrabecular space; Tr.N, number of trabeculae.